Fusion Pharmaceuticals Inc. announced the company has entered into a strategic research collaboration with 48 Hour Discovery Inc. (48HD) to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors. Under the agreement, Fusion has global rights to develop and commercialize any peptides discovered under the collaboration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.55 USD | +0.14% |
|
-.--% | +124.25% |
Jun. 04 | Fusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete | MT |
Jun. 04 | Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Biotechnology Index | CI |
- Stock Market
- Equities
- FUSN Stock
- News FUSN PHAR
- Fusion Pharmaceuticals Announces Research Collaboration with 48Hour Discovery to Develop Peptide-Based Radiopharmaceuticals